Calypso Biotech, a preclinical-stage spin-off from Merck Serono, develops therapeutic antibodies for severe diseases of the gastro-intestinal tract.

Cooperation possibilities

Calypso Biotech is willing to enter into collaboration(s) to support the pharmacological validation of CALY-001 and CALY-002 in translational medicine experiments, develop biomarkers, and support IND-enabling studies, including manufacturing.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2013
  • Number of employees in Switzerland
    1-9
Key business